Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

BACKGROUND: We previously found that administration of an interleukin 2/diphtheria toxin conjugate (DAB/IL2; Denileukin Diftitox; ONTAK) to stage IV melanoma patients depleted CD4(+)CD25(HI)Foxp3(+ )regulatory T cells and expanded melanoma-specific CD8(+ )T cells. The goal of this study was to asses...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Telang, Sucheta, Rasku, Mary Ann, Clem, Amy L, Carter, Karen, Klarer, Alden C, Badger, Wesley R, Milam, Rebecca A, Rai, Shesh N, Pan, Jianmin, Gragg, Hana, Clem, Brian F, McMasters, Kelly M, Miller, Donald M, Chesney, Jason
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2011
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3293785/
https://ncbi.nlm.nih.gov/pubmed/22165955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-515
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker